http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2561599-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4426ebe16fccfb5a37dc44e9889ddfe2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a8d06c7b84761a1981a65c7a3e3e0a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a09d3ed0648d70e1019b174936f1412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26956fb0a244a39b678a26bd3e8c2db9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea87bbda076af18b77fb51acb620053f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_551ab8079b820cddbc287a05e0eb9b6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_240d154ecb7a767d326f9b69eab5fba7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da2688c56ea1395d254e3de1b8e2f873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd766759e52d89f4252a88dc2e3e02fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3b307850da8f54fcd887935595daec4 |
| publicationDate | 2015-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2561599-C1 |
| titleOfInvention | Method of predicting development of immune disorders under impact of strontium with application of immunogenetic criteria |
| abstract | FIELD: medicine.SUBSTANCE: to predict the development of immune disorders in patients living on territories with the high content of strontium in the environment, sampling of blood in the patients from the territory with the higher content of strontium in objects of the environment was carried out. In the said sample determined is the content of strontium in the blood samples of the patients, with the content of strontium higher than the background value, the content of lymphocytes CD8is determined. After that, a separated fraction of CD8lymphocytes is divided into two parts, one of which is subjected to incubation with strontium, and the second is used as a control one, with the incubation being realised by the introduction of 10 mg/l of strontium into the CD8sample. Then, an amount of ribonucleic acid RNA is determined in both samples of CD8lymphocytes by its isolation from separated CD8cells, performed is a reaction of the reverse RNA transcription into deoxyribonucleic acid DNA, in which the quantity of the alpha defensin gene is determined. In determination the gene of GAPDH household is used as internal control. After that the level of the relative expression of the alpha defensin gene is calculated, taking as a spontaneous expression the level referring to the control CD8sample, with the level, referring to the CD8sample, into which strontium was introduced, being taken as the induced expression. A conclusion about immune disorders in the patient, associated with the impact of strontium, is made by the index of the expression, which equals the ratio of the induced expression to the spontaneous expression. If the said index is lower than 0.7, the development of an immunodeficiency state is predicted, and if the index is higher than 3, the development of a proliferative status in the immune system, on the condition of the simultaneous detection of higher than 1.5-fold exceedance of strontium in blood in comparison with the background one.EFFECT: prediction of the immune disorders, associated with the impact of strontium, due to the application of the immunogenetic criteria.2 tbl, 3 ex |
| priorityDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 247.